Company Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Country | United States |
Founded | 2015 |
IPO Date | Jul 18, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 76 |
CEO | Alexander Sapir |
Contact Details
Address: 26 Landsdowne Street Cambridge, Massachusetts 02139 United States | |
Phone | 617 651 8851 |
Website | fulcrumtx.com |
Stock Details
Ticker Symbol | FULC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001680581 |
CUSIP Number | 359616109 |
ISIN Number | US3596161097 |
Employer ID | 47-4839948 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Alexander C. Sapir | Chief Executive Officer, President and Director |
Alan A. Musso C.M.A., CPA | Chief Financial Officer |
Curtis G. Oltmans J.D. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
Mel Hayes | Executive Vice President of Patient Experience |
Dr. Bradley E. Bernstein M.D., Ph.D. | Founder |
Dr. Michael R. Green | Founder |
Dr. Rudolf Jaenisch M.D., Ph.D. | Founder |
Dr. Tsun-Huei Lee M.D., Ph.D. | Founder |
Dr. Danny Reinberg | Founder |
Gregory Tourangeau | Controller and Principal Accounting Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SCHEDULE 13G | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 13, 2024 | 10-Q | Quarterly Report |
Nov 13, 2024 | 8-K | Current Report |
Nov 12, 2024 | 8-K | Current Report |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |